Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.
Abstract
Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
Overview
CoChat Summary
TL;DR
The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.
Key findings
- In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
- Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
- In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
- qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.
Methods
- Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
- Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
- Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.
Limitations
- The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
- The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
- Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While highly active anti-retroviral therapy (HARRT) has dramatically decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of HIV-1 proviruses 5 .”
What the sources say
- Partly supportedcites [5] Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388 (2012). sourceExperimental — accuracy not yet measured
The Introduction describes the latent reservoir as a major barrier to HIV-1 eradication. In “The latent reservoir in resting CD4+ T cells,” the paper says reactivation alone may not purge that reservoir, but it also reports that SAHA can perturb it in vivo. Thus, the paper supports the lack of an established strategy to eliminate latent infection, not the categorical claim that no strategy effectively targets it. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fortunately, the CRISPR/Cas9 system has the advantage in size compared with TALENs 22 .”
What the sources say
- Partly supportedcites [22] Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. (2013). sourceExperimental — accuracy not yet measured
The Future directions section says the large size of TALENs may limit delivery by size-restricted vectors. It does not compare TALEN size with CRISPR/Cas9 size, so it supports the TALEN size concern but not the claimed comparative advantage. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triple TF resulted in a significant decrease in the mean percentage of GFP positive cells from 40.8% to 2.1% ( p = 0.0001) was observed.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we successfully disrupted the expression of HIV-1 provirus utilizing the CRISPR/Cas9 system ( Fig. 1 ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar reduction in GFP expression was observed in c5 and c19 cells transfected with the T5 CRISPR/Cas9 system after 5-Aza-dC/TSA treatment ( Fig. 3A and B ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1-infected human 293 T cells.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ebina et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs)”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function [10].”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, this proof of concept is certainly applicable to any other cell type, including T-lymphoid cells (Fig. S6) (12,13), astrocytes, and neural stem cells”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., & Koonin, E. V. (2006) · Biology Direct · doi:10.1186/1745-6150-1-7 · Cited by 1,199
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
Jordan, A., Bisgrove, D., & Verdin, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg188 · Cited by 914
Cited by
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
“targeted CRISPR-Cas9 technique was shown to efficiently cleave and mutate the long terminal repeat sites of HIV-1 and also to remove internal viral genes from the chromosome of infected cells (132, 133).”
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
“Laboratory results from Ebina and Hu et al.(144,147) showed that CRISPR/Cas9 not only could specifically eradicate latent HIV infection but also could prevent new HIV infection.”
ResultDelivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1infected human 293 T cells.”
MethodCRISPR/Cas9 in Genome Editing and Beyond
Wang, H., La Russa, M., & Qi, L. S. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014607 · Cited by 1,110
“For example, when Cas9 is introduced into infected cells together with sgRNAs targeting crucial viral genomic elements, it helps to inactivate or clear the viral genome and, thereby, defends the cells or organism from infections with HIV (113, 114), hepatitis B virus (115–117), human papillomavirus (118), and Epstein–…”
BackgroundCRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Barrangou, R., & Marraffini, L. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.011 · Cited by 832
“The viral resistance upside is illustrated by a recent report showing excision of HIV-1 provirus in human (Ebina et al., 2013), further highlighting the broad promise of this technology for viral immunity beyond the natural hosts of CRISPR-Cas systems.”
BackgroundCRISPR/Cas9 for genome editing: progress, implications and challenges
Zhang, F., Wen, Y., & Guo, X. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu125 · Cited by 683
“disrupted the long-terminal repeat promoter of HIV-1 genome using CRISPR/Cas9, which significantly decreased HIV-1 expression in infected human cells (72).”
BackgroundDiverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems
Mohanraju, P., Makarova, K. S., Zetsche, B., Zhang, F., Koonin, E. V., & van der Oost, J. (2016) · Science · doi:10.1126/science.aad5147 · Cited by 671
Genome Engineering with Targetable Nucleases
Carroll, D. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035418 · Cited by 568
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405186111 · Cited by 527
“Also, various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs) (12, 13).”
BackgroundResultProgrammable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems
Gomaa, A. A., Klumpe, H. E., Luo, M. L., Selle, K., Barrangou, R., & Beisel, C. L. (2014) · mBio · doi:10.1128/mbio.00928-13 · Cited by 433
“Overall, CRISPR-Cas systems offer a unique opportunity for the selective and titratable removal of microorganisms for industrial and medical purposes, which can be added to the ever-expanding applications of this versatile immune system (11, 20, 23, 47, 48).”
BackgroundNaturally Occurring Off-Switches for CRISPR-Cas9
Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., Lee, J., Edraki, A., Shah, M., Sontheimer, E. J., Maxwell, K. L., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.017 · Cited by 391
“…gene therapy to correct inherited disease, for sequence-specific targeting of pathogens to treat infectious disease, and many other applications (Bikard et al., 2014; Ebina et al., 2013; Gomaa et al., 2014; Kaminski et al., 2016; Ousterout et al., 2015; Wu et al., 2013; Yin et al., 2014).”
The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo
Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386
Microglial Cells: The Main HIV-1 Reservoir in the Brain
Wallet, C., De Rovere, M., Van Assche, J., Daouad, F., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Van Lint, C., Rohr, O., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00362 · Cited by 368
“The first targeted DNA sequence by the CRISPR/Cas9 technology was the NFKB binding site located in the HIV-1 LTR (Ebina et al., 2013).”
BackgroundUse of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells
Liao, H.-K., Gu, Y., Diaz, A., Marlett, J., Takahashi, Y., Li, M., Suzuki, K., Xu, R., Hishida, T., Chang, C.-J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7413 · Cited by 336
In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models
Yin, C., Zhang, T., Qu, X., Zhang, Y., Putatunda, R., Xiao, X., Li, F., Xiao, W., Zhao, H., Dai, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.012 · Cited by 273
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections
van Diemen, F. R., Kruse, E. M., Hooykaas, M. J. G., Bruggeling, C. E., Schürch, A. C., van Ham, P. M., Imhof, S. M., Nijhuis, M., Wiertz, E. J. H. J., & Lebbink, R. J. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005701 · Cited by 290
“The CRISPR/Cas9 system has also been engineered to selectively modify dsDNA viruses [23 – 30], positive-sense single stranded RNA viruses, such as Hepatitis C [31] and integrated HIV proviral DNA in human cells [32 – 36].”
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 283
“It was observed that CRISPR-Cas9 can mutate LTRs in the DNA of HIV-1 provirus, leading to the breakdown of latent HIV-1 provirus.(60) In a negative feedback regulation of HIV-1, the Cas9 gene was placed under the control of a minimal HIV-1 promoter to express Cas9 in HIV-1 contagious cells.”
BackgroundCRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion
Ali, Z., Ali, S., Tashkandi, M., Zaidi, S. S.-E.-A., & Mahfouz, M. M. (2016) · Scientific Reports · doi:10.1038/srep26912 · Cited by 272
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication
Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 244
“In addition to these effective tools for gene function studies, sequence-specific nucleases could be used as potential treatments against viruses, such as HIV (Ebina et al., 2013), HBV (Bloom et al., 2013; Chen et al., 2014; Cradick et al., 2010), HPV (Mino et al., 2013), and HSV (Bi et al., 2014).”
Kennedy, E. M., Bassit, L. C., Mueller, H., Kornepati, A. V. R., Bogerd, H. P., Nie, T., Chatterjee, P., Javanbakht, H., Schinazi, R. F., & Cullen, B. R. (2015) · Virology · doi:10.1016/j.virol.2014.12.001 · Cited by 209
“, 2014) were shown to effectively cleave and inactivate viral DNA in both HIV-1 and HPV-infected human cells (Ebina et al., 2013; Hu et al., 2014; Kennedy et al., 2014), and we therefore wished to test whether Cas9/sgRNA combinations specific for the HBV DNA genome might be able to also cleave and reduce HBV DNA level…”
CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape
Wang, Z., Pan, Q., Gendron, P., Zhu, W., Guo, F., Cen, S., Wainberg, M. A., & Liang, C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.042 · Cited by 231
“, 2015), and HIV type 1 (HIV-1) (Dampier et al., 2014; Ebina et al., 2013; Hu et al., 2014; Li et al., 2015; Liao et al., 2015; Zhu et al., 2015).”
BackgroundZhen, S., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 215
Li, C., Guan, X., Du, T., Jin, W., Wu, B., Liu, Y., Wang, P., Hu, B., Griffin, G. E., Shattock, R. J., et al. (2015) · Journal of General Virology · doi:10.1099/vir.0.000139 · Cited by 192
“Using a pair of sgRNAs targeting the LTR of HIV-1, it was shown that HIV-1 provirus can be removed from the genome of infected cell lines (Ebina et al., 2013; Hu et al., 2014).”
BackgroundMethodRNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection
Wang, J., & Quake, S. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410785111 · Cited by 220
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
BackgroundPrinciples, Applications, and Biosafety of Plant Genome Editing Using CRISPR-Cas9
El-Mounadi, K., Morales-Floriano, M. L., & Garcia-Ruiz, H. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.00056 · Cited by 219
Zhen, S., Hua, L., Takahashi, Y., Narita, S., Liu, Y.-H., & Li, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.014 · Cited by 219
“Molecular-targeting therapy with Cas9 is expected to prevent the development for disease caused by foreign genes, such as human immunodeficiency virus (HIV) infection, by inhibiting expression of genes [24].”
CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape
Wang, G., Zhao, N., Berkhout, B., & Das, A. T. (2016) · Molecular Therapy · doi:10.1038/mt.2016.24 · Cited by 215
Understanding HIV Latency: The Road to an HIV Cure
Dahabieh, M. S., Battivelli, E., & Verdin, E. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-092112-152941 · Cited by 216
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA
Zhu, W., Lei, R., Le Duff, Y., Li, J., Guo, F., Wainberg, M. A., & Liang, C. (2015) · Retrovirology · doi:10.1186/s12977-015-0150-z · Cited by 215
“In support of our data, recent studies reported suppression of the HIV-based vectors using the CRISPR/Cas9 system [19,20].”
Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study
Kaminski, R., Bella, R., Yin, C., Otte, J., Ferrante, P., Gendelman, H. E., Li, H., Booze, R., Gordon, J., Hu, W., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.41 · Cited by 203
Linking CRISPR-Cas9 interference in cassava to the evolution of editing-resistant geminiviruses
Mehta, D., Stürchler, A., Anjanappa, R. B., Zaidi, S. S.-E.-A., Hirsch-Hoffmann, M., Gruissem, W., & Vanderschuren, H. (2019) · Genome Biology · doi:10.1186/s13059-019-1678-3 · Cited by 197
“Repaired viral genomes have been detected previously in two earlier studies in stable transgenic plants [2, 3], as well as in a study with a viral-vector-delivered CRISPR-Cas9 system in model plants [4] and in studies aimed at engineering virus resistance in mammalian systems [18, 19].”
BackgroundCRISPR-Cas9: a new and promising player in gene therapy
Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C., & Li-Juan, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102968 · Cited by 200
Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197
Lentivirus pre-packed with Cas9 protein for safer gene editing
Choi, J. G., Dang, Y., Abraham, S., Ma, H., Zhang, J., Guo, H., Cai, Y., Mikkelsen, J. G., Wu, H., Shankar, P., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.27 · Cited by 192
Progress and Prospects of CRISPR/Cas Systems in Insects and Other Arthropods
Sun, D., Guo, Z., Liu, Y., & Zhang, Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00608 · Cited by 190
“Several studies have successfully used CRISPR/Cas9 technology in gene therapy by disrupting a viral gene, such as HIV-1 or hepatitis B genes (Ebina et al., 2013; Seeger and Sohn, 2014; Liao et al., 2015; Pellagatti et al., 2015).”
BackgroundApplication of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Xiao, Q., Guo, D., & Chen, S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00069 · Cited by 179
“The first CRISPR/Cas9 application in the prevention of HIV-1 infection was performed in 2013 by disruption of latent HIV-1 provirus (Ebina et al., 2013).”
BackgroundMethodInfluentialZhang, B. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30064 · Cited by 179
“In 2013, a study suggests that CRISPR/Cas9 genome editing can be a useful tool for treating HIV infection (Ebina et al., 2013), in which they show that CRISPR/Cas9 system can be used to efficiently cleave and mutate LTR sequences in HIV genome and further affected HIV infection.”
BackgroundCRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages
Martel, B., & Moineau, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku628 · Cited by 178
“The CRISPR-Cas9 engineering system has now been adapted and widely used with high efficiency for editing the genome of cells from humans (21– 23), monkeys (24), livestock (25–27), plants (28–30), rabbits (31), rodents (32–34), amphibians (35,36), fishes (37), insects (38,39), nematodes (40), yeasts (41), bacteria (42)…”
Advances in CRISPR therapeutics
Chavez, M., Chen, X., Finn, P. B., & Qi, L. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00636-2 · Cited by 176
Tang, X., Du, A., & Kou, L. (2018) · WIREs Computational Molecular Science · doi:10.1002/wcms.1361 · Cited by 168
Exploring the potential of genome editing CRISPR-Cas9 technology
Singh, V., Braddick, D., & Dhar, P. K. (2017) · Gene · doi:10.1016/j.gene.2016.11.008 · Cited by 160
“viruses such as HIV-1 (Ebina et al., 2013; Zhu et al., 2015), hepatitis B virus (Lin et al.”
BackgroundMethodInfluentialNuclear landscape of HIV-1 infection and integration
Lušić, M., & Siliciano, R. F. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.162 · Cited by 201
Liu, X., Hao, R., Chen, S., Guo, D., & Chen, Y. Z. (2015) · Journal of General Virology · doi:10.1099/vir.0.000159 · Cited by 159
“The application of this technology to virus research has also been reported, such as the genome editing of Epstein–Barr virus and herpes simplex virus (Yuen et al., 2015), and the eradication of human immunodeficiency virus infection (Cradick et al., 2013; Ebina et al., 2013).”
MethodHigh-efficiency targeted editing of large viral genomes by RNA-guided nucleases
Bi, Y., Sun, L., Gao, D., Ding, C., Li, Z., Li, Y., Cun, W., & Li, Q. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004090 · Cited by 148
“used the CRISPR-Cas9 system to disrupt the latent HIV-1 provirus [32].”
MethodCRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Dai, W.-J., Zhu, L., Yan, Z., Xu, Y., Wang, Q., & Lu, X. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.58 · Cited by 148
Maggio, I., Holkers, M., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2014) · Scientific Reports · doi:10.1038/srep05105 · Cited by 149
Inhibition of HSV-1 Replication by Gene Editing Strategy
Roehm, P. C., Shekarabi, M., Wollebo, H. S., Bellizzi, A., He, L., Salkind, J., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep23146 · Cited by 128
CRISPR/Cas9 technology as a potent molecular tool for gene therapy
Karimian, A., Azizian, K., Parsian, H., Rafieyan, S., Shafiei‐Irannejad, V., Kheyrollah, M., Yousefi, M., Majidinia, M., & Yousefi, B. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27972 · Cited by 158
Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape
Lebbink, R. J., de Jong, D. C. M., Wolters, F., Kruse, E. M., van Ham, P. M., Wiertz, E. J. H. J., & Nijhuis, M. (2017) · Scientific Reports · doi:10.1038/srep41968 · Cited by 158
“Cas9 endonuclease has previously proven effective in targeting double stranded DNA viruses 20–25 and viruses with a double stranded DNA intermediate such as HBV 26–34 and HIV 35–41 .”
Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus
Campbell, L. A., Coke, L. M., Richie, C. T., Fortuno, L. V., Park, A. Y., & Harvey, B. K. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.002 · Cited by 143
“Furthermore, we showed that gesiclemediated delivery of the Cas9 RNP complex containing gRNAs targeting the HIV LTR can produce site-specific mutations, proviral copy number loss, and decreased HIV proviral activity, consistent with other findings.9,10 To our knowledge, this is the first instance where a gesicle and C…”
BackgroundResultInfluentialBarriers for HIV Cure: The Latent Reservoir
Castro‐Gonzalez, S., Colomer-Lluch, M., & Serra-Moreno, R. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0118 · Cited by 154
“reported the successful removal of HIV-1 proviruses in infected Jurkat T cells with CRISPR/ Cas9 by targeting the HIV-1 LTRs.(251) In another study, by targeting the HIV-1 Rev region in the provirus, latently HIV-1-infected Jurkat cells were efficiently inactivated.”
MethodPliatsika, V., & Rigoutsos, I. (2015) · Biology Direct · doi:10.1186/s13062-015-0035-z · Cited by 141
“Thanks to its conceptual simplicity and power the system was quickly adapted for many uses in the cells of higher organisms [7-12].”
BackgroundNanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics
Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0267-9 · Cited by 142
“Although this group used Lipofectamine 2000 to transfect the separate pDNAs (one encoding sgRNA targeting the LTR of HIV; the other encoding Cas9) into HeLa cells, they used electroporation for the more clinically relevant T cell line.”
InfluentialWang, G., Zhao, N., Berkhout, B., & Das, A. T. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.057 · Cited by 130
Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski‐Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U. C., Grundhoff, A. T., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3467 · Cited by 140
Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication
Wang, J., Xu, Z.-W., Liu, S., Zhang, R.-Y., Ding, S.-L., Xie, X.-M., Long, L., Chen, X.-M., Zhuang, H., & Lu, F.-M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i32.9554 · Cited by 126
Farasat, I., & Salis, H. M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004724 · Cited by 127
“By forcing the host to repair these precision DNA cuts, the CRISPR/Cas9 system allows recombinant DNA to be inserted at desired genome locations, and therefore can be used for performing high-throughput gene knockouts, loss-of-function screening, artificial immunization, removal of latent genome-encoded viruses, and s…”
BackgroundTargeting Cdk11 in osteosarcoma cells using the CRISPR‐cas9 system
Feng, Y., Sassi, S. O., Shen, J. K., Yang, X., Gao, Y., Osaka, E., Zhang, J., Yang, S., Cao, Y., Mankin, H. J., et al. (2014) · Journal of Orthopaedic Research® · doi:10.1002/jor.22745 · Cited by 113
CRISPR-mediated Activation of Latent HIV-1 Expression
Limsirichai, P., Gaj, T., & Schaffer, D. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.213 · Cited by 121
CRISPR-based technologies: prokaryotic defense weapons repurposed
Terns, R. M., & Terns, M. P. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.01.003 · Cited by 120
Gao, Z., Fan, M.-H., Das, A. T., Herrera-Carrillo, E., & Berkhout, B. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa226 · Cited by 118
Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein
Chen, R., Huang, H., Liu, H., Xi, J., Ning, J., Zeng, W., Shen, C., Zhang, T., Yu, G., Xu, Q., et al. (2019) · Small · doi:10.1002/smll.201902686 · Cited by 114
Gantz, V. M., & Bier, E. (2015) · BioEssays · doi:10.1002/bies.201500102 · Cited by 104
Zhen, S., Lu, J., Wang, L., Sun, X., Zhang, J., Li, X., Luo, W., & Zhao, L. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.10.002 · Cited by 117
“Recently, CRISPR/Cas9 has been developed as a promising new tool to suppress gene expression [25,26].”
MethodCRISPR/Cas9 for Human Genome Engineering and Disease Research
Xiong, X., Chen, M., Lim, W. A., Zhao, D., & Qi, L. S. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022258 · Cited by 116
Ophinni, Y., Inoue, M., Kotaki, T., & Kameoka, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-26190-1 · Cited by 117
Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9
Yoder, K. E., & Bundschuh, R. A. (2016) · Scientific Reports · doi:10.1038/srep29530 · Cited by 103
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 107
Engineering large viral DNA genomes using the CRISPR‐Cas9 system
Suenaga, T., Kohyama, M., Hirayasu, K., & Arase, H. (2014) · Microbiology and Immunology · doi:10.1111/1348-0421.12180 · Cited by 100
“The CRISPR-Cas9 system is reportedly useful for editingHIV genome integrated into host cell genome (32).”
BackgroundCRISPR/Cas System and Factors Affecting Its Precision and Efficiency
Javaid, N., & Choi, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761709 · Cited by 120
“The new HIV infection is prevented by eliminating the HIV-1 genome from patients (Ebina et al., 2013; Hu et al., 2014).”
BackgroundSingh, V., Gohil, N., Ramirez-Garcia, R., Braddick, D., & Fofié, C. K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26165 · Cited by 96
“It has also been used for the programmable eradication of human viruses from cell lines and from patients, includingHIV-1 [Ebina et al., 2013; Zhu et al., 2015], hepatitis B [Kennedy et al., 2015; Zhen et al., 2015], hepatitis C [Price et al., 2015], andHPV [Kennedy et al., 2014; Liu et al., 2015].”
MethodInfluentialEfficient resistance to grass carp reovirus infection in JAM-A knockout cells using CRISPR/Cas9
Ma, J., Fan, Y., Zhou, Y. K., Liu, W., Jiang, N., Zhang, J., & Zeng, L. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.02.039 · Cited by 95
RNA interference approaches for treatment of HIV-1 infection
Bobbin, M. L., Burnett, J., & Rossi, J. J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0174-y · Cited by 103
Removal of HIV DNA by CRISPR from Patient Blood Engrafts in Humanized Mice
Bella, R., Kaminski, R., Mancuso, P., Young, W., Chen, C., Sariyer, R., Fischer, T., Amini, S., Ferrante, P., Jacobson, J. M., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.021 · Cited by 92
“In accord with this observation, several other laboratories have assessed the efficacy of CRISPR technology in editing the HIV-1 genome in a variety of cell models.(13,14) An important consideration that arose from these recent studies was the appearance of mutant virus that may stem from insertions or deletions (inde…”
ResultBlock-And-Lock: New Horizons for a Cure for HIV-1
Moranguinho, I., & Valente, S. T. (2020) · Viruses · doi:10.3390/v12121443 · Cited by 105
CRISPR-Cas based antiviral strategies against HIV-1
Wang, G., Zhao, N., Berkhout, B., & Das, A. T. (2017) · Virus Research · doi:10.1016/j.virusres.2017.07.020 · Cited by 94
The therapeutic application of CRISPR/Cas9 technologies for HIV
Saayman, S. M., Ali, S. A., Morris, K. V., & Weinberg, M. S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036736 · Cited by 104
“It may also be that the innate immune sys- tem of T cells reacts adversely to foreign DNA [53], a problem which may be overcome by administering in vitro transcribed mRNA [54].”
BackgroundInfluentialZhu, Y. (2022) · BioMed Research International · doi:10.1155/2022/9978571 · Cited by 117
“Ebina et al. and Hu et al. used CRISPR/Cas9 technology to edit the cells with integrated HIV – 1 genes and successfully restricted the activation and replication of the virus by generating mutations at the HIV – 1 fragments [79, 80], opening up a new way for HIV treatment.”
CRISPR genome engineering and viral gene delivery: A case of mutual attraction
Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 87
Genome editing in crop improvement: Present scenario and future prospects
Miglani, G. S. (2017) · Journal of Crop Improvement · doi:10.1080/15427528.2017.1333192 · Cited by 90
“2007), TALENs (Ebina et al. 2013; Holkers et al. 2013, 2014), and CRISPR/Cas9 (Kabadi et al.”
BackgroundDubey, A. K., Gupta, V. K., Kujawska, M., Orive, G., Kim, N., Li, C.-Z., Mishra, Y. K., & Kaushik, A. K. (2022) · Journal of nanostructure in chemistry · doi:10.1007/s40097-022-00472-7 · Cited by 88
“Using dormant HIV-1-infected human 293 T cells, calcium phosphate transfection was utilised to transfer plasmid DNA containing Cas9 and sgRNA, which was engineered to assault the provirus genome, prohibiting viral proteins from being produced and removing inner genetic material from recipient cell nucleus [231, 232].”
MethodDetect and destroy: CRISPR-based technologies for the response against viruses
Freije, C. A., & Sabeti, P. C. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.003 · Cited by 83
“This disruption resulted in less HIV-1 RNA following reactivation in Jurkat cells (Ebina et al., 2013).”
Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction
Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M. H., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020152 · Cited by 93
Engineering virus resistance via CRISPR–Cas systems
Mahas, A., & Mahfouz, M. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.06.002 · Cited by 74
Synthetic AAV/CRISPR vectors for blocking HIV‐1 expression in persistently infected astrocytes
Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov‐Blagojevic, M., Drukker, M., Desbordes, S. C., Grimm, D., et al. (2017) · Glia · doi:10.1002/glia.23254 · Cited by 83
“We targeted the HIV-1 proviral LTR, because it is required for expression of all viral products (Frankel & Young, 1998; Pereira, 2000) and because other studies have demonstrated the feasibility of this approach (Ebina et al., 2013; Hu et al., 2014; Kaminski et al., 2016; Zhu et al., 2015).”
BackgroundResultAntiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans
Soppe, J. A., & Lebbink, R. J. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.04.005 · Cited by 83
CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication
Li, H., Wang, S., Dong, X., Li, Q., Li, M., Li, J., Guo, Y., Jin, X., Zhou, Y., Song, H., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.01.028 · Cited by 86
“Based on this system, the CRISPR-Cas9 genome-editing technique has emerged and been used for the development of therapeutics for many viral diseases caused by pathogenic viruses that make a double-stranded RNA (dsDNA) intermediate in their replication cycles,(10) such as DNA hepatitis B virus (HBV), human papillomavir…”
MethodNewer Gene Editing Technologies toward HIV Gene Therapy
Manjunath, N., Yi, G., Dang, Y., & Shankar, P. (2013) · Viruses · doi:10.3390/v5112748 · Cited by 77
“DNA, providing a way to eliminate HIV latency [97].”
BackgroundCRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection
Wollebo, H. S., Bellizzi, A., Kaminski, R., Hu, W., White, M. K., & Khalili, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136046 · Cited by 81
CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review
Bharathkumar, N., Abraham, S., Meera, P., Aksah, S., Muthu, K., Saravanan, K. M., & Anand, T. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00422-8 · Cited by 80
Advances toward Curing HIV-1 Infection in Tissue Reservoirs
Henderson, L. J., Reoma, L. B., Kovacs, J. A., & Nath, A. (2019) · Journal of Virology · doi:10.1128/jvi.00375-19 · Cited by 85
“This excises the full integrated provirus between the target sequences, though at a much lower frequency than silencing via insertions or deletions (indels) introduced by NHEJ (126, 127, 129).”
BackgroundInfluentialAtkins, A., Chung, C.-H., Allen, A. G., Dampier, W., Gurrola, T. E., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. L. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.673022 · Cited by 88
The clinical applications of genome editing in HIV
Wang, C. X., & Cannon, P. M. (2016) · Blood · doi:10.1182/blood-2016-01-678144 · Cited by 85
Gene Editing by Extracellular Vesicles
Kostyushev, D. S., Kostyusheva, A., Brezgin, S., Vv, S., Volchkova, E. V., Lukashev, A. N., & Chulanov, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197362 · Cited by 77
CRISPR/Cas9-The ultimate weapon to battle infectious diseases?
Doerflinger, M., Forsyth, W. O., Ebert, G., Pellegrini, M., & Herold, M. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12693 · Cited by 77
Chen, S., Hou, C., Bi, H., Wang, Y., Xu, J. Q., Li, M., James, A. A., Huang, Y., & Tan, A. (2017) · Journal of Virology · doi:10.1128/jvi.02465-16 · Cited by 74
“The CRISPR/Cas9 system has been utilized to efficiently eradicate viruses in cell culture and mouse models of human disease, including the hepatitis B virus (HBV) (11, 12), Epstein-Barr virus (13, 14), and human immunodeficiency virus type 1 (HIV-1) in both preintegration and provirus stages (15, 16), providing initia…”
MethodAdvances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 106
Metadata
- Authors
- Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ebina, Hirotaka
- Venue
- Scientific Reports
- Published
- 2013-08-26
- Volume
- 3
- Issue
- 1
- Pages
- 2510-2510
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3752613
- OpenAlex
- W1966452674
- Cited by
- 565
- References
- 28
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24115008)
- Japan Society for the Promotion of Science (24790438, 24390112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
- MeSH terms
- HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.